Abstract:Shina Song, 1, 2 Xiaofeng Li, 1 Xuting Xue, 3 Wenping Dong, 2 Changxin Li 1 1 Department of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China; 2 Department of Geriatrics, General Hospital of TISCO, Taiyuan, People's Republic of China; 3 Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, The First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China Correspondence: Wenping Dong, Department of Geriatrics, General Hospital of TISCO, North Street, Xinhualing District, Taiyuan, Shanxi Province, 030009, People's Republic of China, Tel +86 13703581782, Email Changxin Li, Department of Neurology, The First Hospital of Shanxi Medical University, Jiefangnan Road 85, Taiyuan, Shanxi Province, 030001, People's Republic of China, Tel +86 13834635428, Email High temperature requirement A1 (HTRA1) is a member of the serine protease family, comprising four structural domains: IGFBP domain, Kazal domain, protease domain and PDZ domain. HTRA1 encodes a serine protease, a secreted protein that is widely expressed in the vasculature. HTRA1 regulates a wide range of physiological processes through its proteolytic activity, and is also involved in a variety of vascular abnormalities-related diseases. This article reviews the role of HTRA1 in the development of vascular abnormalities-related hereditary cerebral small vessel disease (CSVD), age-related macular degeneration (AMD), tumors and other diseases. Through relevant research advances to understand the role of HTRA1 in regulating signaling pathways or refolding, translocation, degradation of extracellular matrix (ECM) proteins, thus directly or indirectly regulating angiogenesis, vascular remodeling, and playing an important role in vascular homeostasis, further understanding the mechanism of HTRA1's role in vascular abnormality-related diseases is important for HTRA1 to be used as a therapeutic target in related diseases. Keywords: HTRA1, vascular anomalies, cerebral small vessel disease, AMD, tumor High temperature requirement A1 (HTRA1) is a family of highly conserved serine proteases involved in protein quality control. This protein is widely expressed from prokaryotes to eukaryotes and exists in humans as four homologues, HTRA1, HTRA2, HTRA3 and HTRA4. 1 Originally found in E. coli, HTRA1 is an important component of the heat shock response 2,3 and encodes a widely expressed serine protease that is significantly expressed in the vasculature, 1,4 which has both chaperone and serine protease activities and is involved in many physiological processes, particularly extracellular matrix (ECM) remodeling 5–7 and transforming growth factor-β (TGF-β) signaling. 1,8–11 HTRA1 plays an important role in cell proliferation, migration, and apoptosis in addition to controlling protein aggregation through refolding, translocation, or degradation. 12 HTRA1 is commonly expressed in normal human tissues, but at different levels in different tissues and organs, further suggesting that HTRA1 may play different roles in different cell types. HTRA1 genes are associated with cerebral small vessel disease, 13,14 age-related macular degeneration (AMD), 15 multisite tumors, 16–19 arthritis, 20 pre-eclampsia 21 and other microvascular and macrovascular diseases. The pathogenesis is mainly due to impaired vascular function. 22 This review discusses the mechanisms of HTRA1's role in the vasculature and the progress of research on related diseases. Further understanding of the direct or indirect role of HTRA1 in the vasculature may help us to develop HTRA1 as a therapeutic target. Cerebral small vessel disease is a common clinical cerebrovascular disease that can lead to stroke and dementia. 25% of strokes and 45% of dementia are caused by CSVD. Its harmful effects have recently received more and more attention. The clinical manifestations of cerebral small vessel disease are diverse, ranging from asymptomatic to various neurological symptoms, which can cause confusion in diagnosis and treatment. 23 Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL) is a relatively rare hereditary small vessel disease of the brain caused by a homozygous mutation in the HTRA1 gene. The first patient with CARASIL was diagnosed in Japan in 1965, and the clinical manifestations of the disease are mainly cognitive impairment, recurrent strokes, low back pain and hair loss. 24 The pathological changes observed in patients with CARASIL broadly include marked thinning of the outer membrane of small cerebral arteries, massive loss of smoot -Abstract Truncated-

The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis

High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis

Progress in the Study of the Role and Mechanism of HTRA1 in Diseases Related to Vascular Abnormalities

C1Q/TNF-related Protein 4 Expression Correlates with Herpes Simplex Encephalitis Progression

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis

Proteomic profile of extracellular vesicles from plasma and CSF of multiple sclerosis patients reveals disease activity-associated EAAT2

Whole-exome sequencing in 16,511 individuals reveals a role of the HTRA1 protease and its substrate EGFL8 in brain white matter hyperintensities

A novel heterozygous HTRA1 mutation is associated with autosomal dominant hereditary cerebral small vessel disease

Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis

TNF-α: A serological marker for evaluating the severity of hippocampal sclerosis in medial temporal lobe epilepsy?

Lessons from the Cerebrospinal Fluid Analysis of HTLV-1-Infected Individuals: Biomarkers of Inflammation for HAM/TSP Development

High Level of Serum and Cerebrospinal Fluid of Heparan Sulfate and Hyaluronic Acid Might Be a Biomarker of Severity of Neuromyelitis Optica

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes

Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy

Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis

HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis

Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

A role for vessel‐associated extracellular matrix proteins in multiple sclerosis pathology

Overexpression of HTRA1 Leads to Down-Regulation of Fibronectin and Functional Changes in RF/6A Cells and HUVECs